Basic and Clinical Research of Pregnancy-Induced Hypertension (BCRPIH)
Collect Blood Pressure, Blood, Amniotic Fluid, Placenta and Other Samples From Normal Pregnant Women, Patients With Pregnancy-induced Hypertension and Those Who Have Experienced Miscarriage, and Conduct Tests on Them.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Qian Wang, PHD
- Phone Number: 13587638653
- Email: wqian84@163.com
Study Locations
-
-
Zhejiang
-
Wenzhou, Zhejiang, China, 325000
- Recruiting
- The Second Affiliated Hospital of Wenzhou Medical University
-
Contact:
- Qian Wang, PHD
- Phone Number: 13587638653
- Email: wqian84@163.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Healthy pregnant women, patients with miscarriage, etc.
Exclusion Criteria:
- Heart disease, infections, etc. in pregnant women Uncooperative patients
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
control group
Healthy pregnant women
|
observation
|
|
PIH group
Pregnancy-induced hypertension patients
|
observation
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
PIH
Time Frame: Early pregnancy:Weeks 1 to 12 (the first to third months of pregnancy) ;mid-pregnancy:Weeks 13 to 27 (the 4th to 6th month of pregnancy) ;post-delivery period:Weeks 28 to 40 (the 7th to 9th months of pregnancy);the day of delivery。
|
the content of GPR18 type macrophages
|
Early pregnancy:Weeks 1 to 12 (the first to third months of pregnancy) ;mid-pregnancy:Weeks 13 to 27 (the 4th to 6th month of pregnancy) ;post-delivery period:Weeks 28 to 40 (the 7th to 9th months of pregnancy);the day of delivery。
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
PIH
Time Frame: delivery
|
Blood pressure
|
delivery
|
|
PIH
Time Frame: delivery
|
SPM content
|
delivery
|
|
PIH
Time Frame: delivery
|
Spiral artery morphology
|
delivery
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Qian Wang, The Second Affiliated Hospital of wenzhou Medical University Longwan Branch
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SAHoWMU-CR2025-03-134
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.